BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.

Margherita AmbrosiniDavid TougeronDominik ModestRosine GuimbaudScott KopetzMarie DecraeckerStefano KimClelia CoutzacGeraldine PerkinsEmily AlouaniFederica MarmorinoSimon PernotFrank A SinicropeElena ElezPauline ParentChiara CremoliniFilippo PietrantonioSara LonardiClaire GalloisJulien Taieb

Published in: European journal of cancer (Oxford, England : 1990) (2024)

Our results show that BRAFm dMMR/MSI-H mCRC patients benefit from BRAFi+EGFRi+/-MEKi after progression under ICIs. Despite lower ORR and DCR, the outcome is not different from that observed in pMMR/MSS BRAFm CRC and is in line with the results of the BEACON registration trial.

Keyphrases

metastatic colorectal cancer
end stage renal disease
wild type
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
epidermal growth factor receptor
peritoneal dialysis
phase iii
cell proliferation
patient reported
pi k akt